Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: An evaluation based on a 1-year randomised controlled trial

PharmacoEconomics

Volumn 20, Issue 1, 2002, Pages 61-70

  Maetzel, Andreas ^a   Strand, Vibeke ^b   Tugwell, Peter ^c   Wells, George ^c   Bombardier, Claire ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b STANFORD UNIVERSITY   (United States)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LEFLUNOMIDE; METHOTREXATE;

ADULT; AGED; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG EFFICACY; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HUMANS; ISOXAZOLES; METHOTREXATE; MIDDLE AGED; ONTARIO; TREATMENT OUTCOME;

EID: 0036174734     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220010-00006     Document Type: Article

References (17)

1. Economic burden of rheumatoid arthritis: A systematic review
2. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: A 12 year study
3. A cost effectiveness analysis of cyclosporine in rheumatoid arthritis
4. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): A decision analysis model
5. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone
6. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate
7. Preliminary definition of improvement in rheumatoid arthritis
8. Statistical analysis in pharmacoeconomic studies: A review of current issues and standards
9. How should cost data in pragmatic randomised trials be analysed?
10. Analysis of cost data in randomized trials: An application of the non- parametric bootstrap
11. Why health care costs more in the US: Comparing health care expenditures between systemic lupus erythematosus patients in Stanford and Montreal
12. Clinical improvement as reflected in measures of function and health- related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial
13. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone